Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?

Journal of Cardiology

Volumn 52, Issue 1, 2008, Pages 39-48

  Tanaka, Shinichiro ^a   Nishigaki, Kazuhiko ^a   Ojio, Shinsuke ^a   Okubo, Munenori ^a   Yasuda, Shinji ^a   Ishihara, Yoshiyuki ^a   Kubota, Tomoki ^a   Takasugi, Nobuhiro ^a   Kawamura, Itta ^a   Yamaki, Takahiko ^a   Ushikoshi, Hiroaki ^a   Aoyama, Takuma ^a   Kawasaki, Masanori ^a   Takemura, Genzou ^a   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angina pectoris; Angiography; H2 blocker; Proton pump inhibitor; Ventricular function

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; TICLOPIDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; IN VITRO STUDY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; THROMBUS; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 47049128655     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.05.004     Document Type: Article

References (16)

1. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al.; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-68.
2. Kasanuki H. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2004). Circ J 68 Suppl. IV (2004) 1153-1219
3. Sugano K. Japanese guideline for the management of gastric ulcer. Nippon Rinsho 62 (2004) 1389-1395
4. Hinrichsen H., Halabi A., and Kirch W. Clinical aspects of cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol 35 (1995) 107-116
5. Ooie T., Saikawa T., Hara M., Ono H., Seike M., and Sakata T. H2-blocker modulates heart rate variability. Heart Vessels 14 (1999) 137-142
6. Halabi A., and Kirch W. Cardiovascular effects of omeprazole and famotidine. Scand J Gastroenterol 27 (1992) 753-756
7. Schillinger W., Teucher N., Sossalla S., Kettlewell S., Werner C., Raddatz D., et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation 116 (2007) 57-66
8. Dodge H.T., Sandler H., Ballew D.W., and Lord Jr. J.D. The use of biplane angiocardigraphy for the measurement of left ventricular volume in man. Am Heart J 60 (1960) 762-776
9. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
10. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
11. Schulz M., and Schmoldt. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58 (2003) 447-474
12. Katashima M., Yamamoto K., Tokuma Y., Hata T., Sawada Y., and Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of protein pump inhibitors omeprazole, lansoprazole, and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 23 (1998) 19-26
13. Tateno M., and Nakamura N. Phaze I study of lansoplazole (AG-1749) antiulcer agent-capsule form. J Clin Ther Med 7 (1991) 51-62
14. Graham D.Y., Agrawal N.M., Campbell D.R., Haber M.M., Collis C., Lukasik N.L., et al., NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 28 162 (2002) 169-175
15. Yenisehirli A., and Onur R. Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium. Eur J Pharmacol 519 (2005) 259-266
16. Leeder S.R., Mitchell P., Liew G., Rochtchina E., Smith W., and Wang J.J. Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the Blue Mountains Eye Study. J Am Soc Nephrol 17 (2006) 279-284